Vericel (VCEL) Finished Goods (2014 - 2026)
Vericel (VCEL) posted Finished Goods of $2.8 million for Q2 2026, down 9.54% sequentially from $3.1 million in Q1 2026, and down 20.98% YoY from $3.5 million in Q2 2025.
Vericel (VCEL) Finished Goods (2014 - 2026) Analysis & Trends
Vericel has reported Finished Goods for 13 years, with the latest figure at $2.8 million in Q2 2026.
- Quarterly Finished Goods fell 20.98% year-over-year to $2.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.8 million (down 20.98% YoY) and the FY2025 annual result came in at $3.0 million, up 1.61% from the prior year.
- Finished Goods retreated to $2.8 million in Q2 2026 per VCEL's latest filing, from $3.1 million in the prior quarter.
- Over five years, Finished Goods peaked at $4.0 million in Q3 2025 and troughed at $49000.0 in Q3 2022.
- A 5-year average of $1.6 million and a median of $1.3 million in 2024 frame the typical range for Finished Goods.
- The sharpest annual moves came in 2022 and 2024: Finished Goods dropped 27.94% in 2022, then soared 1414.29% in 2024.
- Over 5 years, Finished Goods stood at $53000.0 in 2022, then jumped by 898.11% to $529000.0 in 2023, then soared by 462.38% to $3.0 million in 2024, then climbed by 1.61% to $3.0 million in 2025, then declined by 7.44% to $2.8 million in 2026.
- According to Business Quant data, Finished Goods over the past three periods registered $2.8 million, $3.1 million, and $3.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.80 Mn |
| Mar 31, 2026 | 3.09 Mn |
| Dec 31, 2025 | 3.02 Mn |
| Sep 30, 2025 | 3.99 Mn |
| Jun 30, 2025 | 3.54 Mn |
| Mar 31, 2025 | 3.69 Mn |
| Dec 31, 2024 | 2.98 Mn |
| Sep 30, 2024 | 2.05 Mn |
| Jun 30, 2024 | 1.61 Mn |
| Mar 31, 2024 | 954,000.00 |
| Dec 31, 2023 | 529,000.00 |
| Sep 30, 2023 | 218,000.00 |
| Jun 30, 2023 | 173,000.00 |
| Mar 31, 2023 | 63,000.00 |
| Dec 31, 2022 | 53,000.00 |
| Sep 30, 2022 | 49,000.00 |
| Jun 30, 2022 | 71,000.00 |
| Mar 31, 2022 | 64,000.00 |
| Dec 31, 2021 | 61,000.00 |
| Sep 30, 2021 | 68,000.00 |